RENAL PROSTAGLANDIN EFFLUX INDUCED BY VASOPRESSIN, DDAVP AND ARACHIDONIC ACID: CONTRASTING PROFILE AND SITES OF RELEASE

Prostaglandin (PG) efflux into ureteral (UE) and venous effluents (VE) of rabbit isolated perfused kidneys was determined by superfusion bioassay and radioimmunoassay (RIA), in response to injections of arginine-vasopressin (AVP), the non-pressor vasopressin analogue 1-deamino-8-D-arginine vasopressin (dDAVP) and arachidonic acid (AA). dDAVP (10-1000 ng) failed to stimulate renal PG release, whereas AVP (10-100 ng) and AA (10-50 micrograms) caused a dose-dependent release of PG. AVP evoked PG release into both effluents with release into the VE greater than UE at high doses. In contrast, PG release by AA was almost exclusively into the VE. Indomethacin (2.8 X 10(-6) mol/l) abolished AVP- and AA-induced PG efflux in both effluents, and vasodepressor responses to AA. PGE2 was the predominant PG released in response to AVP in both effluents whereas AA released primarily 6-keto-PGF1 alpha. The contrasting sites and profile of released PG suggest that exogenous AA and AVP stimulate the release of PG from different regions/cell types within the kidney.     

Exaggerated renal thromboxane and prostaglandin release by angiotensin II in suprarenal aortic coarctation hypertension

The ability of angiotensin II and arachidonic acid to release immunoreactive prostaglandins into venous and ureteral effluents of rabbit isolated perfused kidneys was examined 7 days after suprarenal aortic coarctation (SRAC) or sham operation (SHAM). Renal vascular responses to angiotensin II were significantly enhanced in SRAC and accompanied by an enhanced venous efflux of bioassayable prostaglandins. Angiotension II-induced release of immunoreactive PGE2, PGF2 alpha, 6-keto PGF1 alpha and TxB2 into the venous effluent was exaggerated in SRAC. As angiotensin II did not stimulate TxB2 efflux in the SHAM group the induction of TxB2 release by SRAC is particularly noteworthy. These changes in eicosanoid release in response to angiotensin II were not mimicked by arachidonic acid administration. These results suggest that in renovascular hypertension angiotensin II-induced prostaglandin release is primarily augmented in the vascular compartment and is consistent with the sensitivity of renal function to cyclooxygenase inhibitors in renovascular hypertension.     

Response of peripheral collateral arteries in the dog to prostaglandins E1, E2, F2 alpha, and I2 (prostacyclin)

Prostaglandins (PG) E2, E2, E2 alpha, and I2 [prostacyclin (PGI2)] were tested in vitro on collateral arteries that enlarge following chronic occlusion of the femoral artery in the dog. After contraction with an ED50 dose of KCl, serial doses of a PG were added. Collateral arteries relaxed significantly to PGI2 (10(-7)--10(-5) M). Normal, similarly sized branch arteries did not relax. The contractile response of collateral arteries to PGE1, PGE2, and PGF2 alpha was qualitatively similar to that of branch arteries, but the magnitude of the responses for collateral arteries was PGF2 alpha = PGE2 greater than PGE1. The magnitude of the response for branch arteries was PGF2 alpha much greater than PGE2 greater than PGE1. The effects of the PGs on anterior tibial arteries from the contralateral limb and on anterior tibial arteries exposed to low pressure below the occlusion did not differ. Thus the lowered pressure in the limb with the occluded femoral artery was not responsible for differences in the effects of the PGs on collateral arteries. Collateral arteries are more sensitive to the relaxant effects of PGI2 in high doses and are less sensitive to the contractile effects of other PGs, particularly PGF2 alpha, than similarly sized arteries. This suggests that therapeutic doses of PGI2 may increase blood flow to ischemic areas.     

Prostaglandins of the E series inhibit release of noradrenaline in rat hypothalamus by a mechanism unrelated to classical alpha 2 adrenergic presynaptic inhibition

The effects of eight different prostanoid derivatives (PGs) on the in vitro release of noradrenaline (NA) from rat hypothalamic slices are reported. Prostaglandin E2 (10(-8)-10(-5) M), which does not interfere with the [3H]NA uptake mechanism, inhibited [3H]NA release induced by K+-evoked depolarization. The rank order of inhibition of release of NA for the PGs was: PGE2 greater than PGE1 greater than PGA2 greater than 16, 16-dimethyl-PGE2 greater than 11-epi-PGE2 greater than or equal to 8-iso-PGE2 greater than PGF2 alpha greater than PGD2. It has recently been shown that PGs of the E series specifically bind with a high affinity to membrane preparations of rat hypothalamus. A similar rank order was found for the activity of these PGs in displacing [3H]PGE2 from its binding sites, suggesting that the effect of PGEs on release of NA is mediated by an interaction with PGE2 receptors. Under the same experimental conditions, 10(-6) M clonidine (an alpha 2 adrenoceptor agonist) diminished, and 10(-6) M yohimbine (an alpha adrenoceptor antagonist) increased [3H]NA release, supporting the existence of alpha 2 auto-inhibition. Exposure to 10(-6) M of the alpha 1, alpha 2 adrenergic receptor antagonist phentolamine, a concentration which by itself had no effect on overflow of [3H]NA, blocked the inhibitory effect of clonidine, but failed to antagonize the inhibitory action of PGE2. Moreover, the action of clonidine and yohimbine remained unaffected when PG synthesis was blocked with indomethacin.(ABSTRACT TRUNCATED AT 250 WORDS)     

The two-step model of prostaglandin signal termination: in vitro reconstitution with the prostaglandin transporter and prostaglandin 15 dehydrogenase

Termination of prostaglandin (PG) signaling has been proposed to involve carrier-mediated uptake across the plasma membrane followed by cytoplasmic oxidation. Here, we tested this hypothesis directly by coexpressing the PG uptake carrier prostaglandin transporter (PGT) in various cell types with and without human PG 15 dehydrogenase (PG15DH). In HeLa cells, which express neither PGT nor PG15DH, exogenously added PGE2 or PGF2alpha were rapidly oxidized to the 13, 14-dihydro, 15-keto metabolites only when PGT and PG15DH were coexpressed, directly confirming the two-step hypothesis. Cells expressing PG15DH that were broken open formed more PG metabolites than cells in which the PGs could gain access to PG15DH only via PGT. Similar results were obtained using the human prostate cancer cell line LNCaP, in which endogenous PG15DH is induced after exposure to dihydrotestosterone. Because PGT in vivo is expressed in renal collecting duct epithelia, we also expressed PGT in Madin-Darby canine kidney cells grown on filters, where it mediated both the active uptake of PGE2 across the apical membrane and the transepithelial transport of PGE2 to the basolateral compartment. When PG15DH was coexpressed with PGT in these epithelial monolayers, about half of the PGE2 taken up apically was oxidized to 13, 14-dihydro, 15-keto-PGE2, which in turn exited the cells nondirectionally into both the apical and basolateral compartments. Our data represent reconstitution of the longstanding model of PG metabolism consisting of sequential carrier-mediated PG uptake, cytoplasmic oxidation, and diffusional efflux of the PG metabolite.     

Profile of prostaglandins generated in the detrusor muscle of rat urinary bladder: effects of adenosine triphosphate and adenosine

The generation and release of PGE2, PGF2 alpha, PGD2, TXB2 and 6-keto-PGF1 alpha in the rat detrusor muscle were studied by means of radioimmunoassays. The effect of ATP (0.1 mmol/1) and adenosine (0.1 mmol/1) on the content and profile of PGs in the incubation medium was investigated. It was found that PGE2 and 6-keto-PGF1 alpha accounted for more than 80% of the total PG activity. ATP increased the amounts of PGs in the incubation medium (percentage change of the control values, N = 6: PGE2 54.53 +/- 12.69, PGF2 alpha 31.01 +/- 8.82, PGD2 44.52 +/- 12.36, TXB2 17.29 +/- 10.45, 6-keto-PGF1 alpha 36.62 +/- 5.0) but did not change their profile. Adenosine had no effect on either content or profile of the PGs. The results suggest that ATP but ot adenosine may activate PG biosynthesis via P2-purinoceptor-mediated mechanisms.     

Endothelium-dependent and -independent mechanisms of action of acetylcholine in monkey and dog isolated arteries

In helical strips of monkey coronary and mesenteric arteries and dog mesenteric arteries partially contracted with prostaglandin (PG)F2 alpha, the mechanism of action of acetylcholine (ACh) has been analyzed by the use of pharmacological antagonists and by the endothelium-derived relaxing factor (EDRF) bioassay and the 6-keto PGF1 alpha radioimmunoassay. In conclusion, ACh releases vasodilator substance(s) from endothelium (EDRF) and also PGs from subendothelial tissues. Vasoconstrictor PGs appear to counteract the dilator action of EDRF in monkey coronary arteries, whereas vasodilator PG, possibly PGI2, appears to facilitate the relaxation caused by EDRF in monkey and dog mesenteric arteries.     

Comparison of responses to angiotensin II of dog mesenteric arteries and veins.

Responses to angiotensin II (AII), arachidonic acid (AA) and prostaglandin (PG) I2 were compared in helical strips of dog mesenteric arteries and veins. Arterial strips contracted in response to AII, whereas venous strips responded with a transient, slight contraction followed by a moderate relaxation. The peptide-induced responses were abolished by treatment with saralasin, but were not influenced by ONO3708, an inhibitor of vasoconstrictor PG actions, or by endothelium denudation. Treatment with indomethacin potentiated the contractile response of the arteries and reversed the relaxant response of veins to a contraction. The concentration of exogenous PGI2 methylester needed to produce a tension development similar to that induced by PGI2 released by AII was greater in the mesenteric arteries than in the veins. The amount of 6-keto PGF1 alpha in the bathing media measured by radioimmunoassay was increased in the arteries and veins stimulated by AII. Exogenously applied PGI2 elicited relaxations of similar magnitude in the arteries and veins. AA-induced relaxations were greater in the veins; indomethacin suppressed the arterial and venous relaxations. The magnitude of the endothelium-dependent relaxation induced by A23187 was similar in the arteries and veins. It appears that the heterogenous responses to AII of dog mesenteric arteries and veins are due mainly to the difference in the AII receptors responsible for smooth muscle contraction and also to the difference in the ability to produce and liberate PGI2. The synthesis and the action of EDRF (endothelium-derived relaxing factor) does not seem to differ in the arteries and veins.     

Failure of anti-inflammatory steroids to inhibit prostaglandin release from the hydronephrotic rabbit kidney

The release of prostaglandins E2, F2 alpha, I2 and thromboxane A2 from isolated perfused normal and hydronephrotic rabbit kidneys was investigated by extraction and radioimmunoassay. In both types of kidneys, basal PG efflux increased with time and was not altered by co-perfusion with dexamethasone or hydrocortisone. Several vasoactive substances at 1 to 4 micrograms (e.g., bradykinin, angiotensin II, substance P, noradrenaline and vasopressin) caused release of additional amounts of prostaglandins. PGE2 and 6-keto PGF1 alpha were the major prostanoids detected, but substantial amounts of PGF2 alpha were also found. Thromboxane A2 was not released from normal kidneys. In hydronephrotic kidneys there was greatly augmented release of prostaglandins E2 and I2, some increases in PGF2 alpha, and the appearance of substantial amounts of thromboxane A2 (measured as immunoreactive TXB2) when the kidneys were challenged with angiotensin, bradykinin and vasopressin, and smaller augmentation of the response to noradrenaline and substance P. There was no evidence that these evoked increases in renal PG output could be inhibited by dexamethasone or hydrocortisone. Some explanations for the failure of steroids to alter prostanoid metabolism from arachidonate in rabbit kidney are discussed, and it is proposed that there are clear exceptions to the concept that steroids inhibit prostaglandin generation in intact tissues.     

The release of prostanoids during the acute pulmonary response to E. coli endotoxin in anaesthetized cats.

1 The administration of E. coli endotoxin (2 mg/kg i.v.) to anaesthetized cats results in a characteristic acute pulmonary response. This consists of increases in pulmonary artery pressure and airways resistance and a reduction in lung compliance. 2 Plasma concentrations of prostaglandin E2 (PGE2), PGF2 alpha, thromboxane B2 and 6-keto PGF1 alpha were measured by radioimmunoassay in aortic and pulmonary arterial blood samples before, during and after the acute pulmonary response to endotoxin. 3 Endotoxin administration resulted in the rapid release of PGF2 alpha and thromboxane B2 from the lungs. The time course of this release was parallel to that of the pulmonary hypertensive and airways responses to endotoxin. PGE2 and 6-keto PGF1 alpha were released more gradually and with greater variations between individual animals. 4 During the delayed shock phase (2 h after endotoxin) the concentrations of PGE2, PGF2 alpha and 6-keto PGF1 alpha were once again elevated in both the aorta and pulmonary artery. Thromboxane B2 concentrations were not increased at this time. 5 These results suggest that PGF2 alpha and thromboxane A2 may be mediators of the acute pulmonary responses to endotoxin.     

Differential regulation of the cyclooxygenase pathway in starch elicited rat peritoneal macrophages by prostaglandin E2, U-44069, a stable endoperoxide analogue and dibutyryl-cyclic AMP

The basal and carrageenin-stimulated release of thromboxane (TX) B2, the stable product of TXA2, 6-ketoPGF1 alpha, the stable breakdown product of prostacyclin (PGI2) and prostaglandin (PG) E2 from 24 h starch elicited rat peritoneal macrophages was inhibited by dibutyryl-cyclic AMP (db-cAMP). PGE2 also inhibited the release of TXA2 and 6-keto-PGF1 alpha whereas the stable endoperoxide analogue, U-44069, stimulated PGE2 and 6-keto PGF1 alpha release but inhibited TXB2 release. The effects of all three mediators tested were related to an increase of M? intracellular cAMP content.     

Differential effect of platelet-activating factor (PAF) receptor antagonists on peptide and PAF-stimulated prostaglandin release in unilateral ureteral obstruction

Unilateral ureteral obstruction (UUO) results in increased renal resistance as well as in exaggerated prostaglandin (PG) release from the obstructed hydronephrotic kidney (HNK). We have reported previously that platelet-activating factor (PAF) dose-dependently stimulates the release of PGs from both the HNK and unobstructed contralateral kidney (CLK), with CLK release being 10% that of the HNK. In the present report, we studied the interaction of PAF with its receptor by examining the effects of PAF-receptor antagonists on the release of PGs from the isolated perfused rabbit HNK and CLK stimulated by PAF; angiotensin II (AII), and bradykinin (BK) were also used as agonists. In the HNK, kadsurenone (3 microM) inhibited PAF-stimulated PGE2 and thromboxane B2 (TxB2) release by 28.2 and 62.5% respectively. CV-3988 (20 microM) and triazolam (5 microM) also preferentially diminished PAF-stimulated TxB2 release. In addition, all three drugs significantly diminished BK- and AII-stimulated TxB2 release, while CV-3988 was the only antagonist to affect peptide-stimulated PGE2 release. While effective against agonist-stimulated PG synthesis, these drugs had no direct effect on arachidonic acid metabolism to PGs. Furthermore, in the CLK, CV-3988 had no effect on BK- or AII-stimulated PGE2 release, whereas it totally inhibited PAF-stimulated release of PGE2. These results show that PAF-receptor antagonists in the HNK preferentially inhibit TxB2 release whether stimulated by PAF, AII or BK; in the CLK only PAF-stimulated PG release is affected. This biochemical difference may be of physiological significance and explain some of the functional differences between the HNK and CLK. Therefore, PAF may be an important mediator of some of the biochemical and functional changes associated with UUO.     

Enhancement by prostacyclin of the contractility of the guinea-pig airways smooth muscle

Aerosolized prostacyclin (PGI2) potentiated the increase in pulmonary resistance to inflation induced by serotonin, prostaglandin F2 alpha (PGF2 alpha), acetylcholine and histamine in the guinea-pig. This was not due to a reflex, nor to further production of PG cyclooxygenase derivatives. PGI2 and PGF2 alpha induced contraction of the parenchyma lung strip of the guinea-pig, which could be inhibited by polyphloretin phosphate and by PGE1. Since PGF2 alpha failed to potentiate the bronchial responses to acetylcholine, histamine or serotonin, under conditions where PGI2 was effective, the in vitro similarities between the two PGs cannot explain the in vivo results. The ability of PGI2 to potentiate bronchial responses was not shared by the other PGs. Since the latter are either bronchoconstrictor agents by themselves (PGF2 alpha and PGD2), or bronchodilators (PGE1, PGE2), our hypothesis is that PGI2 potentiates the responses of the bronchi to various agonists by a mechanism similar to that which accounts for the potentiation of acute inflammation and pain by PGE1 and PGE2, the latter being ineffective in enhancing the bronchial responses because of the associated bronchodilator activity.     

Evidence that prostaglandins activate calcium channels to enhance basal and stimulation-evoked catecholamine release from bovine adrenal chromaffin cells in culture

The effects of prostaglandins (PGs) on catecholamine (CA) secretion and Ca2+ fluxes were studied in a primary culture of bovine chromaffin cells. PGD2, PGF2 alpha and PGE2 induced CA release from cultured bovine chromaffin cells in a concentration dependent manner (0.03-3 microM). PGD2, PGF2 alpha and PGE2 at 3 microM elicited maximum CA release of 0.043 +/- 0.001, 0.059 +/- 0.008, 0.062 +/- 0.002 micrograms/10(6) cells, respectively. Three micromolar of PGD2, PGF2 alpha and PGE2 enhanced CA release induced by acetylcholine (ACh) in a degree of 186 +/- 10, 206 +/- 6, 150 +/- 4% of control respectively. PGs also enhanced CA release induced by 20 mM K+, veratridine and A23187. In Ca2+-free medium, PGs failed to affect basal and caffeine (50 mM)-induced CA release. PGF2 alpha increased 45Ca uptake and showed additive effect with ACh on 45Ca uptake. Nicardipine (0.1-10 microM) suppressed CA release and 45Ca uptake induced by PGF2 alpha, while diltiazem and verapamil failed to affect these responses to PGF2 alpha. BAY K 8644 (1 microM) potentiated CA release and 45Ca uptake evoked by PGF2 alpha. These results suggest that PGs enhance basal and stimulation-evoked CA release from chromaffin cells possibly through facilitation of Ca2+ influx. The mechanisms of action of PGs in adrenal medulla are discussed.     

Cutaneous reactions to intradermal prostaglandins

1. The effects of intradermally injected prostaglandins (PGs) E(1), E(2), F(1alpha) and F(2alpha) have been examined in the rat and in man.2. PGE(1) and PGE(2) caused an increase in local vascular permeability in rat skin; their potency was comparable with that of other putative mediators of inflammation (histamine, bradykinin, and 5-hydroxytryptamine), but PGF(1alpha) and PGF(2alpha) were only slightly active even at a dose of 1 mug.3. Prior administration of mepyramine and methysergide, or depletion of skin mast cell amines with compound 48/80, indicated that PGE(2) exerted its permeability effect in the rat by a release of mast cell amines.4. Nanogramme doses of PGE(1) and PGE(2) or microgramme doses of PGF(1alpha) and PGF(2alpha) injected intradermally into the human forearm induced weal and flare responses.5. It is concluded that prostaglandins E(1) and E(2) can act as intermediates in the production of hyperaemia and oedema resulting from cell damage in the rat and man.     

Age-dependent changes in the synthesis and catabolism of 6 oxo PGE1 and other prostanoids by the rat kidney in vitro

Synthesis and catabolism of 6 oxo PGE1 was assessed in 100,000 g cell-free supernatant fractions of kidneys obtained from rats aged 20, 34 and 70 days. In addition the release of PGI2, TxA2 (measured as 6 oxo PGF1 alpha and TxB2, respectively), PGE2 and PGF2 alpha from kidney slices prepared from these three groups of rats was determined using specific radioimmunoassays. The conversion of PGI2 to 6 oxo PGE1 (but not 13,14 dihydro 15 oxo PGF2 alpha to 13,14 dihydro 15 oxo PGE2) was detected in supernatant fractions of kidneys from 20 day rats. Slices prepared from the kidneys of these animals spontaneously released significant amounts of three prostanoids (6 oxo PGF1 alpha greater than PGE2 greater than PGF2 alpha greater than TxB2 = 0). No formation of 6 oxo PGE1 from exogenous PGI2 was demonstrated in renal 100,000 g supernates from 34 and 70 day rats even though these supernates avidly oxidised 13,14 dihydro 15 oxo PGF2 alpha to 13,14 dihydro 15 oxo PGE2. In these animals the rank order of prostanoid release from kidney slices was PGE2 greater than 6 oxo PGF1 alpha greater than PGF2 alpha greater than TxB2 = 0. The catabolism of 6 oxo PGE1 is also age-dependent. In 20 and 34 day old rats 6 oxo PGE1 and PGE1 incubated with renal 100,000 g supernates undergo loss of biological activity as determined by the ability to inhibit ADP induced human platelet aggregation. In contrast, kidney 100,000 g supernates prepared from 70 day rats convert 6 oxo PGE1 to an unidentified metabolite with more potent anti-aggregatory activity. The possibility that 6 oxo PGE1 has a biological role in the developing rat kidney is discussed.     

Role of endothelium in the response to prostaglandin H2 in isolated dog arteries

Prostaglandin (PG) H2 produced a transient contraction followed by a relaxation in helical strips of dog coronary, mesenteric and renal arteries contracted with PGF2 alpha. The contraction was in the order of mesenteric greater than renal greater than coronary artery. Removal of endothelium abolished the contraction in these arteries and significantly potentiated the relaxation only in mesenteric arteries. The relaxation was greater in mesenteric arteries than in renal and coronary arteries, denuded of endothelium. PGI2-induced relaxations were not influenced by endothelium denudation. In the arteries contracted with K+, PGH2-induced relaxations were attenuated, compared to those contracted with PGF2 alpha. Treatment with ONO3708, an antagonist of vasoconstrictor PGs, abolished the PGH2-induced contraction and potentiated the relaxation in the K+-contracted arteries. The relaxant response was suppressed by diphloretin phosphate, a PG receptor antagonist, as was the response to PGI2. PGH2-induced contractions in dog coronary, mesenteric and renal arteries would be due to vasoconstrictor PGs produced preferentially in the endothelium. However, production of PGI2 from PGH2 in endothelial and subendothelial tissues do not appear to differ.     

The role of eicosanoids in cyclosporine nephrotoxicity in the rat

Nephrotoxicity is the most troublesome complication of cyclosporine (CSA) therapy. The present study was designed to investigate the effects of chronic treatment with CSA on the 24-hr urinary excretion of prostanoids (PGs) and thromboxane (Tx) and on the renal function in the absence or presence of indomethacin. CSA administration to Wistar rats (20 mg/kg/day, i.p.) for 14 days caused a significant increase in plasma creatinine, blood urea nitrogen (BUN), urine osmolality, fractional excretion of sodium and potassium and a reduction in creatinine clearance (CCr) and urine volume. These changes were associated with a significant reduction in urinary excretion of PGE2 (21.1 +/- 3.3 vs 33.0 +/- 2.5 ng/24 hr) and PGF2 alpha (13.4 +/- 1.4 vs 27.9 +/- 3.8 ng/24 hr) and an increase in TxB2 (12.1 +/- 3.0 vs 4.6 +/- 0.5 ng/24 hr), and 6-keto PGF1 alpha (56.2 +/- 7.7 vs 27.7 +/- 1.9 ng/24 hr). However, the synthesis of TxB2 and 6-keto PGF1 alpha by renal medullary and cortical slices prepared from CSA treated rats was not different from values obtained for vehicle treatment. In contrast, PGE2 synthesis by cortical slices prepared from the CSA group was increased. A single injection of indomethacin (10 mg/kg) to vehicle and CSA treated rats resulted in a significant reduction in PGs and TxB2 excretion. This, was associated with a further reduction in CCr (0.81 +/- 0.06 vs 1.03 +/- 0.04 ml/min) and an increase in BUN (38.5 +/- 5.2 vs 28.2 +/- 1.4 mg%) only in the CSA group. We suggest that the vasodilating PGs attenuate the renal toxic effects induced by CSA.     

Potent inhibition of prostaglandin inactivation in rabbit gastric antral mucosal slices by selenium ions in-vitro

The effect of selenium ions on prostaglandin (PG) catabolism and synthesis in rabbit gastric antral mucosal slices has been examined. Selenium ions had a potent inhibitory effect on the inactivation process for PGE2 and PGF2 alpha. Simultaneously, the levels of PGE2 and PGF2 alpha were increased. These results suggest that selenium ions have the potential to increase the levels of biologically active PGs in gastric mucosa by preventing their inactivation and that this effect may represent some pharmacological action of selenium ions.     

Atrial natriuretic peptide and urinary prostaglandins in man.

1. In order to assess the effects of atrial natriuretic factor on the renal biosynthesis of prostaglandins (PG), the urinary excretion of PGE2, PGF2 alpha, 6-keto-PGF1 alpha and thromboxane (Tx)B2 were followed in eight salt-loaded healthy volunteers infused for 2 h with a non hypotensive dose of human atrial natriuretic peptide (hANP, 0.7 nmol min-1). 2. Within 1 h, hANP, infusion produced a marked increase in the urinary PG output, especially of PGE2 and 6-keto-PGF1 alpha (188 +/- 21% and 202 +/- 24% of the pre-infusion values respectively), followed by a significant decrease during the recovery period. 3. No correlations could be uncovered between the urinary excretion of sodium and that of any of the PGs. In contrast, during the infusion of hANP, the urinary output of PGE2 and of 6-keto-PGF1 alpha was found positively related to the urinary flow rate (r = 0.42; P less than 0.05; n = 32 and r = 0.43; P less than 0.05; n = 32 respectively) as well as during the recovery period (r = 0.66, P less than 0.001; n = 32 and r = 0.55; P less than 0.01; n = 32 respectively). 4. It was concluded that, in man, infusion of a non hypotensive dose of hANP is followed by a rise in urinary PG excretion presumably reflecting enhanced renal PG biosynthesis. This increased urinary PG excretion does not seem to be involved in the natriuretic action of hANP but might participate to its diuretic effect.